BerGenBio to present at Jefferies 2017 London Healthcare Conference

Bergen, Norway, 16 November 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the Company will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, on 16 November 2017.

The presentation will be delivered by Richard Godfrey, CEO, and the presented slides are available on the Company’s website: www.bergenbio.com.

-Ends-

Presentasjonen: http://www.bergenbio.com/wp-content/uploads/2017/11/Jefferies_final.pdf